Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...
Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual ...
Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...
– Breadth of Alto’s pipeline and Precision Psychiatry Platform™ will be highlighted across twelve posters and presentations at the Society of Biological Psychiatry and American Society of Clinical ...
The regional agency asked for the research to be undertaken aas the prospect of local projects have become a hot button issue.
The new position would work “develop data-driven strategies to enhance municipal services and support council priorities.” ...
Pharmaceuticals announced that 23 abstracts, including six oral presentations, showcasing compelling Revuforj and Niktimvo data were accepted for presentation at the 67th American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback